HRP20221183T1 - T-stanični receptori anti-kras-g12d - Google Patents
T-stanični receptori anti-kras-g12d Download PDFInfo
- Publication number
- HRP20221183T1 HRP20221183T1 HRP20221183TT HRP20221183T HRP20221183T1 HR P20221183 T1 HRP20221183 T1 HR P20221183T1 HR P20221183T T HRP20221183T T HR P20221183TT HR P20221183 T HRP20221183 T HR P20221183T HR P20221183 T1 HRP20221183 T1 HR P20221183T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- amino acid
- acid sequence
- isolated
- polypeptide chain
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 56
- 229920001184 polypeptide Polymers 0.000 claims 36
- 102000004196 processed proteins & peptides Human genes 0.000 claims 36
- 108090000765 processed proteins & peptides Proteins 0.000 claims 36
- 102000004169 proteins and genes Human genes 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 239000013604 expression vector Substances 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 238000003259 recombinant expression Methods 0.000 claims 5
- 102200006539 rs121913529 Human genes 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 230000002357 endometrial effect Effects 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000002611 ovarian Effects 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/7051—T-cell receptor (TcR)-CD3 complex
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
Claims (24)
1. Izolirani ili pročišćeni TCR specifičan za KRAS G12D, koji sadrži aminokiselinske sljedove SEQ ID NO: 9-11 i (i) SEQ ID NO: 12-14 ili (ii) SEQ ID NO: 20-22.
2. Izolirani ili pročišćeni TCR u skladu s patentnim zahtjevom 1, koji sadrži aminokiselinski slijed SEQ ID NO: 15 i aminokiselinski slijed koji je najmanje 99 % istovjetan aminokiselinskom slijedu (i) SEQ ID NO: 16 ili (ii) SEQ ID NO: 24.
3. Izolirani ili pročišćeni TCR u skladu s patentnim zahtjevom 2, koji sadrži aminokiselinske sljedove SEQ ID NO: 15 i (i) SEQ ID NO: 16 ili (ii) SEQ ID NO: 24.
4. Izolirani ili pročišćeni TCR u skladu s bilo kojim od patentnih zahtjeva 1-3, koji dodatno sadrži:
(A) aminokiselinski slijed koji je najmanje 99 % istovjetan aminokiselinskom slijedu SEQ ID NO: 46, pri čemu:
(i) X na položaju 48 u SEQ ID NO: 46 je Thr ili Cys;
(ii) X na položaju 112 u SEQ ID NO: 46 je Ser, Ala, Val, Leu, Ile, Pro, Phe, Met ili Trp;
(iii) X na položaju 114 u SEQ ID NO: 46 je Met, Ala, Val, Leu, Ile, Pro, Phe ili Trp; i
(iv) X na položaju 115 u SEQ ID NO: 46 je Gly, Ala, Val, Leu, Ile, Pro, Phe, Met ili Trp;
i
(B) aminokiselinski slijed SEQ ID NO: 47, pri čemu je X na položaju 57 u SEQ ID NO: 47 Ser ili Cys.
5. Izolirani ili pročišćeni TCR u skladu s patentnim zahtjevom 4, koji sadrži:
(A) aminokiselinski slijed SEQ ID NO: 46, pri čemu:
(i) X na položaju 48 u SEQ ID NO: 46 je Thr ili Cys;
(ii) X na položaju 112 u SEQ ID NO: 46 je Ser, Ala, Val, Leu, Ile, Pro, Phe, Met ili Trp;
(iii) X na položaju 114 u SEQ ID NO: 46 je Met, Ala, Val, Leu, Ile, Pro, Phe ili Trp;
i
(iv) X na položaju 115 u SEQ ID NO: 46 je Gly, Ala, Val, Leu, Ile, Pro, Phe, Met ili Trp;
i
(B) aminokiselinski slijed SEQ ID NO: 47, pri čemu je X na položaju 57 u SEQ ID NO: 47 Ser ili Cys.
6. Izolirani ili pročišćeni TCR u skladu s bilo kojim od patentnih zahtjeva 1-5, koji sadrži aminokiselinske sljedove koji su najmanje 99 % istovjetni aminokiselinskim sljedovima (i) SEQ ID NO: 50 i 51 ili (ii) SEQ ID NO: 50 i 53.
7. Izolirani ili pročišćeni TCR u skladu s patentnim zahtjevom 6, koji sadrži aminokiselinske sljedove (i) SEQ ID NO: 50 i 51 ili (ii) SEQ ID NO: 50 i 53.
8. Izolirani ili pročišćeni polipeptid specifičan za KRAS G12D koji sadrži aminokiselinske sljedove SEQ ID NO: 9-11 i (i) SEQ ID NO: 12-14 ili (ii) SEQ ID NO: 20-22
pri čemu polipeptid može dodatno sadržavati:
(A) aminokiselinski slijed koji je najmanje 99 % istovjetan aminokiselinskom slijedu SEQ ID NO: 46, pri čemu:
(i) X na položaju 48 u SEQ ID NO: 46 je Thr ili Cys;
(ii) X na položaju 112 u SEQ ID NO: 46 je Ser, Ala, Val, Leu, Ile, Pro, Phe, Met ili Trp;
(iii) X na položaju 114 u SEQ ID NO: 46 je Met, Ala, Val, Leu, Ile, Pro, Phe ili Trp; i
(iv) X na položaju 115 u SEQ ID NO: 46 je Gly, Ala, Val, Leu, Ile, Pro, Phe, Met ili Trp;
i
(B) aminokiselinski slijed SEQ ID NO: 47, pri čemu je X na položaju 57 u SEQ ID NO: 47 Ser ili Cys.
9. Izolirani ili pročišćeni polipeptid specifičan za KRAS G12D u skladu s patentnim zahtjevom 8, pri čemu polipeptid sadrži:
(A) aminokiselinski slijed SEQ ID NO: 46, pri čemu:
(i) X na položaju 48 u SEQ ID NO: 46 je Thr ili Cys;
(ii) X na položaju 112 u SEQ ID NO: 46 je Ser, Ala, Val, Leu, Ile, Pro, Phe, Met ili Trp;
(iii) X na položaju 114 u SEQ ID NO: 46 je Met, Ala, Val, Leu, Ile, Pro, Phe ili Trp; i
(iv) X na položaju 115 u SEQ ID NO: 46 je Gly, Ala, Val, Leu, Ile, Pro, Phe, Met ili Trp;
i
(B) aminokiselinski slijed SEQ ID NO: 47, pri čemu je X na položaju 57 u SEQ ID NO: 47 Ser ili Cys.
10. Izolirani ili pročišćeni polipeptid u skladu s patentnim zahtjevom 8 ili 9, koji sadrži aminokiselinski slijed SEQ ID NO: 15 i aminokiselinski slijed koji je najmanje 99 % istovjetan aminokiselinskom slijedu (i) SEQ ID NO: 16 ili (ii) SEQ ID NO: 24.
11. Izolirani ili pročišćeni polipeptid u skladu s patentnim zahtjevom 10, koji sadrži aminokiselinske sljedove SEQ ID NO: 15 i (i) SEQ ID NO: 16 ili (ii) SEQ ID NO: 24.
12. Izolirani ili pročišćeni polipeptid u skladu s bilo kojim od patentnim zahtjevom 8-11, koji sadrži aminokiselinske sljedove koji su najmanje 99 % istovjetni aminokiselinskim sljedovima (i) SEQ ID NO: 50 i 51 ili (ii) SEQ ID NO: 50 i 53.
13. Izolirani ili pročišćeni polipeptid u skladu s patentnim zahtjevom 12, koji sadrži aminokiselinske sljedove (i) SEQ ID NO: 50 i 51 ili (ii) SEQ ID NO: 50 i 53.
14. Izolirani ili pročišćeni protein specifičan za KRAS G12D koji sadrži (a) prvi polipeptidni lanac koji sadrži aminokiselinske sljedove SEQ ID NO: 9-11 i drugi polipeptidni lanac koji sadrži aminokiselinske sljedove SEQ ID NO: 12-14; ili (b) prvi polipeptidni lanac koji sadrži aminokiselinske sljedove SEQ ID NO: 9-11 i drugi polipeptidni lanac koji sadrži aminokiselinske sljedove SEQ ID NO: 20-22
pri čemu:
(A) prvi polipeptidni lanac može dodatno sadržavati aminokiselinski slijed koji je najmanje 99 % istovjetan aminokiselinskom slijedu SEQ ID NO: 46, pri čemu:
(i) X na položaju 48 u SEQ ID NO: 46 je Thr ili Cys;
(ii) X na položaju 112 u SEQ ID NO: 46 je Ser, Ala, Val, Leu, Ile, Pro, Phe, Met ili Trp;
(iii) X na položaju 114 u SEQ ID NO: 46 je Met, Ala, Val, Leu, Ile, Pro, Phe ili Trp; i
(iv) X na položaju 115 u SEQ ID NO: 46 je Gly, Ala, Val, Leu, Ile, Pro, Phe, Met ili Trp;
i
(B) drugi polipeptidni lanac može dodatno sadržavati aminokiselinski slijed SEQ ID NO: 47, pri čemu je X na položaju 57 u SEQ ID NO: 47 Ser ili Cys.
15. Izolirani ili pročišćeni protein specifičan za KRAS G12D u skladu s patentnim zahtjevom 14, pri čemu:
(A) prvi polipeptidni lanac sadrži aminokiselinski slijed SEQ ID NO: 46, pri čemu:
(i) X na položaju 48 u SEQ ID NO: 46 je Thr ili Cys;
(ii) X na položaju 112 u SEQ ID NO: 46 je Ser, Ala, Val, Leu, Ile, Pro, Phe, Met ili Trp;
(iii) X na položaju 114 u SEQ ID NO: 46 je Met, Ala, Val, Leu, Ile, Pro, Phe ili Trp; i
(iv) X na položaju 115 u SEQ ID NO: 46 je Gly, Ala, Val, Leu, Ile, Pro, Phe, Met ili Trp;
i
(B) drugi polipeptidni lanac sadrži aminokiselinski slijed SEQ ID NO: 47, pri čemu je X na položaju 57 u SEQ ID NO: 47 Ser ili Cys.
16. Izolirani ili pročišćeni protein u skladu s patentnim zahtjevom 14 ili 15, koji sadrži (i) prvi polipeptidni lanac koji sadrži aminokiselinske sljedove SEQ ID NO: 15 i drugi polipeptidni lanac koji sadrži aminokiselinski slijed koji je najmanje 99 % istovjetan aminokiselinskim sljedovima SEQ ID NO: 16; ili
(ii) prvi polipeptidni lanac koji sadrži aminokiselinske sljedove SEQ ID NO: 15 i drugi polipeptidni lanac koji sadrži aminokiselinski slijed koji je najmanje 99 % istovjetan aminokiselinskim sljedovima SEQ ID NO: 24.
17. Izolirani ili pročišćeni protein u skladu s patentnim zahtjevom 16, koji sadrži (i) prvi polipeptidni lanac koji sadrži aminokiselinski slijed SEQ ID NO: 15 i drugi polipeptidni lanac koji sadrži aminokiselinski slijed SEQ ID NO: 16; ili
(ii) prvi polipeptidni lanac koji sadrži aminokiselinski slijed SEQ ID NO: 15 i drugi polipeptidni lanac koji sadrži aminokiselinski slijed SEQ ID NO: 24.
18. Izolirani ili pročišćeni protein u skladu s bilo kojim od patentnih zahtjeva 14-17, pri čemu: (1) prvi polipeptidni lanac sadrži aminokiselinski lanac koji je najmanje 99 % istovjetan aminokiselinskom slijedu SEQ ID NO: 50, a drugi polipeptidni lanac sadrži aminokiselinski slijed koji je najmanje 99 % istovjetan aminokiselinskom slijedu SEQ ID NO: 51; ili (2) prvi polipeptidni lanac sadrži aminokiselinski slijed koji je najmanje 99 % istovjetan aminokiselinskom slijedu SEQ ID NO: 50, a drugi polipeptidni lanac sadrži aminokiselinski slijed koji je najmanje 99 % istovjetan aminokiselinskom slijedu SEQ ID NO: 53.
19. Izolirani ili pročišćeni protein u skladu s patentnim zahtjevom 18, pri čemu: (1) prvi polipeptidni lanac sadrži aminokiselinski slijed SEQ ID NO: 50, a drugi polipeptidni lanac sadrži aminokiselinski slijed SEQ ID NO: 51; ili (2) prvi polipeptidni lanac sadrži aminokiselinski slijed SEQ ID NO: 50, a drugi polipeptidni lanac sadrži aminokiselinski slijed SEQ ID NO: 53.
20. Izolirana ili pročišćena nukleinska kiselina koja sadrži nukleotidni slijed koji kodira TCR u skladu s bilo kojim od patentnih zahtjeva 1-7, polipeptid u skladu s bilo kojim od patentnih zahtjeva 8-13, protein u skladu s bilo kojim od patentnih zahtjeva 14-19, ili rekombinantni ekspresijski vektor koji sadrži nukleinsku kiselinu.
21. Izolirana ili pročišćena stanica domaćin koja sadrži rekombinantni ekspresijski vektor u skladu s patentnim zahtjevom 20, ili populacija stanica domaćina koja sadrži najmanje jedno od izolirane ili pročišćene stanice domaćina.
22. Farmaceutski pripravak koji sadrži TCR u skladu s bilo kojim od patentnih zahtjeva 1-7, polipeptid u skladu s bilo kojim od patentnih zahtjeva 8-13, protein u skladu s bilo kojim od patentnih zahtjeva 14-19, nukleinska kiselina u skladu s patentnim zahtjevom 20, rekombinantni ekspresijski vektor u skladu s patentnim zahtjevom 20, stanica domaćina u skladu s patentnim zahtjevom 21 ili populacija stanica domaćina u skladu s patentnim zahtjevom 21, te farmaceutski prihvatljivi nosač.
23. Postupak utvrđivanja prisutnosti raka kod sisavca, gdje se postupak sastoji od:
(a) stavljanja u kontakt uzorka koji sadrži stanice raka s TCR-om u skladu s bilo kojim od patentnih zahtjeva 1-7, polipeptidom u skladu s bilo kojim od patentnih zahtjeva 8-13, proteinom u skladu s bilo kojim od patentnih zahtjeva 14-19, nukleinskom kiselinom u skladu s patentnim zahtjevom 20, rekombinantnim ekspresijskim vektorom u skladu s patentnim zahtjevom 20, stanicom domaćinom u skladu s patentnim zahtjevom 21, populacijom stanica domaćina u skladu s patentnim zahtjevom 21 ili farmaceutskim pripravkom u skladu s patentnim zahtjevom 22, pri čemu se stvara kompleks; i
(b) utvrđivanja kompleksa,
pri čemu utvrđivanje kompleksa ukazuje na prisutnost raka kod sisavca,
pri čemu rak može biti rak gušterače, kolorektalni rak, rak pluća, endometrija, jajnika ili prostate.
24. TCR u skladu s bilo kojim od patentnih zahtjeva 1-7, polipeptid u skladu s bilo kojim od patentnih zahtjeva 8-13, protein u skladu s bilo kojim od patentnih zahtjeva 14-19, nukleinska kiselina u skladu s patentnim zahtjevom 20, rekombinantni ekspresijski vektor u skladu s patentnim zahtjevom 20, stanica domaćin u skladu s patentnim zahtjevom 21, populacija stanica domaćina u skladu s patentnim zahtjevom 21, ili farmaceutski pripravak u skladu s patentnim zahtjevom 22, namijenjeni upotrebi u liječenju ili sprječavanju raka kod sisavca,
pri čemu rak može biti rak gušterače, kolorektalni rak, rak pluća, endometrija, jajnika ili prostate.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662369883P | 2016-08-02 | 2016-08-02 | |
| PCT/US2017/044615 WO2018026691A1 (en) | 2016-08-02 | 2017-07-31 | Anti-kras-g12d t cell receptors |
| EP17749580.1A EP3494133B1 (en) | 2016-08-02 | 2017-07-31 | Anti-kras-g12d t cell receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20221183T1 true HRP20221183T1 (hr) | 2022-12-09 |
Family
ID=59564253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20221183TT HRP20221183T1 (hr) | 2016-08-02 | 2017-07-31 | T-stanični receptori anti-kras-g12d |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US10611816B2 (hr) |
| EP (2) | EP4159751A1 (hr) |
| JP (3) | JP6993402B2 (hr) |
| KR (1) | KR102527052B1 (hr) |
| CN (2) | CN109790211B (hr) |
| AU (2) | AU2017306038B2 (hr) |
| CA (1) | CA3032870A1 (hr) |
| DK (1) | DK3494133T3 (hr) |
| ES (1) | ES2928051T3 (hr) |
| HR (1) | HRP20221183T1 (hr) |
| HU (1) | HUE060121T2 (hr) |
| IL (2) | IL264425B2 (hr) |
| LT (1) | LT3494133T (hr) |
| PL (1) | PL3494133T3 (hr) |
| PT (1) | PT3494133T (hr) |
| RS (1) | RS63615B1 (hr) |
| SG (2) | SG10201913959WA (hr) |
| SI (1) | SI3494133T1 (hr) |
| WO (1) | WO2018026691A1 (hr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL264425B2 (en) * | 2016-08-02 | 2023-09-01 | Us Secretary Department Of Health And Human Services | t cell receptors against kras-g20 |
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| AU2018335274A1 (en) | 2017-09-20 | 2020-04-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HLA class II–restricted T cell receptors against mutated RAS |
| US20210268091A1 (en) * | 2018-06-19 | 2021-09-02 | Biontech Us Inc. | Neoantigens and uses thereof |
| CN113631172A (zh) * | 2019-01-25 | 2021-11-09 | 宾夕法尼亚大学理事会 | 用于靶向突变型ras的组合物和方法 |
| GB2613715B (en) | 2019-02-20 | 2023-12-06 | Fred Hutchinson Cancer Center | Binding proteins specific for RAS neoantigens and uses thereof |
| CN110172089B (zh) * | 2019-06-11 | 2020-01-07 | 北京鼎成肽源生物技术有限公司 | 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用 |
| CN112110995A (zh) * | 2019-06-19 | 2020-12-22 | 上海交通大学医学院 | 肿瘤新抗原多肽及其用途 |
| CN112760290A (zh) * | 2019-10-21 | 2021-05-07 | 郑州大学 | 携带突变的肿瘤驱动基因的干细胞及其用途 |
| CN112759641B (zh) * | 2019-11-01 | 2023-01-20 | 香雪生命科学技术（广东）有限公司 | 一种识别Kras G12V的高亲和力TCR |
| EP4054626A4 (en) * | 2019-11-05 | 2023-11-29 | Board of Regents, The University of Texas System | HLA-RESTRICTED HORMAD1 T CELL RECEPTORS AND THEIR USES |
| CA3164986A1 (en) | 2019-12-20 | 2021-06-24 | Instil Bio (Uk) Limited | Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof |
| WO2021135178A1 (zh) * | 2019-12-30 | 2021-07-08 | 华夏英泰（北京）生物技术有限公司 | 一种增强型t细胞受体star及其应用 |
| CA3185241A1 (en) * | 2020-07-13 | 2022-01-20 | Noam LEVIN | Hla class ii?restricted drb t cell receptors against ras with g12d mutation |
| KR20230125204A (ko) * | 2020-11-25 | 2023-08-29 | 지니우스 바이오테크놀로지 인코포레이티드 | 항원 특이적인 t 세포 및 이의 제조 및 이용 방법 |
| WO2022183167A1 (en) | 2021-02-25 | 2022-09-01 | Alaunos Therapeutics, Inc. | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
| EP4334361A1 (en) | 2021-05-05 | 2024-03-13 | Immatics Biotechnologies GmbH | Antigen binding proteins specifically binding prame |
| WO2023150562A1 (en) | 2022-02-01 | 2023-08-10 | Alaunos Therapeutics, Inc. | Methods for activation and expansion of t cells |
| CN114920823B (zh) * | 2022-05-27 | 2023-10-17 | 重庆医科大学 | Tcr或其抗原结合片段及其应用 |
| WO2024020537A2 (en) * | 2022-07-22 | 2024-01-25 | Board Of Regents, The University Of Texas System | Cd3-expressing natural killer cells with enhanced function for adoptive immunotherapy |
| CN117777270A (zh) * | 2022-09-29 | 2024-03-29 | 广州医科大学 | 一种t细胞受体(tcr)及其用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5776459A (en) * | 1989-07-19 | 1998-07-07 | Connetics Corporation | TCR V beta 5 peptides |
| US20020150891A1 (en) * | 1994-09-19 | 2002-10-17 | Leroy E. Hood | Diagnostic and therapeutic compositions and methods which utilize the t cell receptor beta gene region |
| US7709002B1 (en) | 1996-04-19 | 2010-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes |
| GB2328689A (en) | 1997-08-27 | 1999-03-03 | Norsk Hydro As | Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer |
| WO2004021995A2 (en) | 2002-09-06 | 2004-03-18 | The Government Of The United States Of America, Represented By The Secretary, Departement Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
| US8216565B2 (en) | 2007-01-12 | 2012-07-10 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | GP100-specific T cell receptors and related materials and methods of use |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| ME02810B (me) | 2010-09-20 | 2018-01-20 | Biontech Cell & Gene Therapies Gmbh | Antigen-specifični t ćelijski receptori i t ćelijski epitopi |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| SI2755997T1 (sl) | 2011-09-15 | 2018-11-30 | The United States of America, as represented by Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health | T-celični receptorji, ki prepoznajo HLA-A1- ali HLA-CW7-omejeni mage |
| CA2853645A1 (en) * | 2011-11-30 | 2013-06-06 | National Cancer Center | Induced malignant stem cells |
| KR20160013049A (ko) * | 2013-06-03 | 2016-02-03 | 노파르티스 아게 | 항-pd-l1 항체 및 mek 억제제 및/또는 braf 억제제의 조합물 |
| GB201313377D0 (en) * | 2013-07-26 | 2013-09-11 | Adaptimmune Ltd | T cell receptors |
| GB201314404D0 (en) | 2013-08-12 | 2013-09-25 | Immunocore Ltd | T Cell Receptors |
| JP6863893B2 (ja) | 2014-11-26 | 2021-04-21 | アメリカ合衆国 | 抗突然変異ｋｒａｓ ｔ細胞受容体 |
| CN115073583A (zh) | 2015-09-15 | 2022-09-20 | 美国卫生和人力服务部 | 识别hla-cw8限制性突变kras的t细胞受体 |
| IL264425B2 (en) * | 2016-08-02 | 2023-09-01 | Us Secretary Department Of Health And Human Services | t cell receptors against kras-g20 |
-
2017
- 2017-07-31 IL IL264425A patent/IL264425B2/en unknown
- 2017-07-31 ES ES17749580T patent/ES2928051T3/es active Active
- 2017-07-31 WO PCT/US2017/044615 patent/WO2018026691A1/en unknown
- 2017-07-31 EP EP22182473.3A patent/EP4159751A1/en active Pending
- 2017-07-31 PT PT177495801T patent/PT3494133T/pt unknown
- 2017-07-31 HU HUE17749580A patent/HUE060121T2/hu unknown
- 2017-07-31 HR HRP20221183TT patent/HRP20221183T1/hr unknown
- 2017-07-31 JP JP2019505220A patent/JP6993402B2/ja active Active
- 2017-07-31 CN CN201780059356.4A patent/CN109790211B/zh active Active
- 2017-07-31 SI SI201731231T patent/SI3494133T1/sl unknown
- 2017-07-31 PL PL17749580.1T patent/PL3494133T3/pl unknown
- 2017-07-31 AU AU2017306038A patent/AU2017306038B2/en active Active
- 2017-07-31 EP EP17749580.1A patent/EP3494133B1/en active Active
- 2017-07-31 SG SG10201913959WA patent/SG10201913959WA/en unknown
- 2017-07-31 CN CN202410214235.4A patent/CN118063591A/zh active Pending
- 2017-07-31 RS RS20220894A patent/RS63615B1/sr unknown
- 2017-07-31 IL IL301894A patent/IL301894A/en unknown
- 2017-07-31 CA CA3032870A patent/CA3032870A1/en active Pending
- 2017-07-31 SG SG11201900654QA patent/SG11201900654QA/en unknown
- 2017-07-31 DK DK17749580.1T patent/DK3494133T3/da active
- 2017-07-31 KR KR1020197005837A patent/KR102527052B1/ko active IP Right Grant
- 2017-07-31 US US16/321,899 patent/US10611816B2/en active Active
- 2017-07-31 LT LTEPPCT/US2017/044615T patent/LT3494133T/lt unknown
-
2020
- 2020-04-02 US US16/838,395 patent/US11208456B2/en active Active
-
2021
- 2021-06-11 US US17/345,390 patent/US11897933B2/en active Active
- 2021-12-03 US US17/541,619 patent/US11840561B2/en active Active
- 2021-12-09 JP JP2021199878A patent/JP7413338B2/ja active Active
-
2023
- 2023-09-21 AU AU2023233125A patent/AU2023233125A1/en active Pending
- 2023-12-27 JP JP2023221526A patent/JP2024045139A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20221183T1 (hr) | T-stanični receptori anti-kras-g12d | |
| JP2019527555A5 (hr) | ||
| HRP20200325T1 (hr) | T-stanični receptori koji prepoznaju mhc razred ii-ograničenog mage-a3 | |
| Panas et al. | Viral and cellular proteins containing FGDF motifs bind G3BP to block stress granule formation | |
| MX2023013883A (es) | Polipeptidos multimericos moduladores de linfocitos t y metodos para su uso. | |
| JP2015535816A5 (hr) | ||
| BR112012011740A2 (pt) | polipeptídeo, composição compreendendo o referido polipeptídeo, complexo de proteína, seqüência de nucleotídeo, vetor de expressão célula, e métodos para a preparação do complexo de proteína, para a preparação de um fviii, e para intensificar uma propriedade farmacocinética no plasma de um fviii | |
| AU2017266905A1 (en) | Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof | |
| ES2662402T3 (es) | Neurotoxinas recombinantes de Clostridium botulinum | |
| CY1118664T1 (el) | Απομονωμενο πολυπεπτιδιο των πρωτεϊνων τοξινης α και τοξινης β toy c. difficile και χρησεις αυτου | |
| WO2017151940A3 (en) | T-cell modulatory multimeric polypeptides and methods of use thereof | |
| AR059300A1 (es) | Peptidos inhibidores de la fusion de vih con propiedades biologicas mejoradas | |
| HRP20212023T1 (hr) | Modulokini temeljeni na il-15 i il-15ralpha sushi domeni | |
| WO2009042570A3 (en) | Modified t cell receptors and related materials and methods | |
| NZ737844A (en) | Vista regulatory t cell mediator protein, vista binding agents and use thereof | |
| NO20090818L (no) | Humant endogent retrovirus polypeptid sammensetninger samt anvendelsesmetoder derav | |
| Yuan et al. | Wnt signaling pathway linked to intestinal regeneration via evolutionary patterns and gene expression in the sea cucumber Apostichopus japonicus | |
| BR112022010153A2 (pt) | Peptídeos, ácido nucleico, polipeptídeo, composição, complexo bioluminescente, métodos, dipeptídeo, sistema e kit | |
| CO2020001654A2 (es) | Proteínas de fijación al antígeno que se fijan a 5t4 y 4-1bb y composiciones y métodos relacionados | |
| BR112021018734A2 (pt) | Receptores de células t e métodos de uso destes | |
| Kuriyama et al. | Inhibitory effect of novel somatostatin peptide analogues on human cancer cell growth based on the selective inhibition of DNA polymerase β | |
| HRP20220525T1 (hr) | Postupci uporabe polinukleotida koji kodiraju ligand ox40 | |
| EP2589658A4 (en) | PARTICLE POLYPEPTIDE OF THE REIC / DKK-3 PROTEIN | |
| MX2019009045A (es) | Nuevas luciferasas y metodos para su uso. | |
| Wang et al. | Characterization of cancer-related somatic mutations in the adenosine A2B receptor |